Given that you clicked on this article, it seems safe to assume you either own stock in Synovus Financial (NYSE: SNV ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers that investors need to know about Synovus stock before deciding whether to buy, sell, or hold it.
As the bank's website tells it, Synovus traces its roots back to 1888 when a mill worker at Eagle and Phenix Mill in Columbus, Georgia "had her dress tangled in the factory machinery, and money sewn into the hem spilled across the floor." The mill's secretary and treasurer thereafter began offering to keep employees' money in a safe and pay them monthly interest on it. And thus was born Synovus Financial. With roughly $27 billion in assets today, the bank has since grown into one of the largest regional banks in the country.
As you can see in the table above, Synovus is still struggling to emerge from the financial crisis. Among other things, its nonperforming loans ratio is 101 basis points higher than the average of the 100-plus banks that I surveyed for this series. In addition, its efficiency ratio shows that virtually all of its revenue is eaten up by the costs of running the bank. And finally, its dividend payout ratio is roughly a third of where most bank investors like to see it. As a side note, Synovus' return on equity is abnormally high due to a large income tax benefit it recorded last year. It's for these reasons, in turn, that shares in the regional lender are trading for a 16% discount to tangible book value.
Hot Bank Companies To Invest In 2015: Sunedison Inc (SUNE)
SunEdison Inc, formerly MEMC Electronic Materials, Inc., incorporated on October 1, 1984, is engaged in the development, manufacture and sale of silicon wafers. The Company is a developer and seller of photovoltaic energy solutions. Through Solar Materials and Solar Energy (SunEdison), it is a developer of solar energy projects. The Company operates in two segments: semiconductor materials and solar energy. The Company�� Solar Energy segment includes the operations of its old Solar Materials segment, as well as its SunEdison business. In the Semiconductor Materials, the Company offers wafers with a variety of features. The Company�� wafers vary in size, surface features, composition, purity levels, crystal properties and electrical properties.
Semiconductor Materials
The Company�� monocrystalline wafers for use in semiconductor applications range in size from 100 millimeter to 300 millimeter and are round in shape for semiconductor customers because of the nature of their processing equipment. Its wafers are used as the starting material for the manufacture of various types of semiconductor devices, including microprocessor, memory, logic and power devices. In turn, these semiconductor devices are used in computers, cellular phones and other mobile electronic devices, automobiles and other consumer and industrial products. Its monocrystalline wafers for semiconductor applications include four general categories of wafers: prime, epitaxial, test/monitor and silicon-on-insulator (SOI) wafers.
The Company�� prime wafer is a polished, pure wafer with an ultraflat and ultraclean surface. The Company�� epitaxial (epi), wafers consist of a thin silicon layer grown on the polished surface of the wafer. Typically, the epitaxial layer has different electrical properties from the underlying wafer. This provides customers with isolation between circuit elements than a polished wafer. Its AEGIS product is designed for certain specialized applications requiring high resis! tivity epitaxial wafers and its MDZ product feature. The AEGIS wafer includes a thin epitaxial layer grown on a standard starting wafer. The AEGIS wafer�� thin epitaxial layer eliminates harmful defects on the surface of the wafer, thereby allowing device manufacturers to increase yields. The Company supplies test/monitor wafers to its customers for use in testing semiconductor fabrication lines and processes. An SOI wafer is a different starting material for the chip making process.
Solar Energy
The Company�� Solar Energy segment provides solar energy services that integrate the design, installation, financing, monitoring, operations and maintenance portions of the downstream solar market to provide a solar energy service to its customers. As of December 31, 2012, SunEdison interconnected over 675 solar power systems representing 989 megawatt of solar energy generating capacity. As of December 31, 2012, SunEdison had 73 megawatt of projects under construction and 2.6 gigawatts in pipeline. In support of its downstream solar business, its Solar Energy segment manufactures polysilicon, silicon wafers and solar modules. Additionally, its Solar Energy segment will sell solar modules to third parties in the event the opportunity aligns with itsinternal needs. It provides its downstream customers with a way to purchase renewable energy by delivering solar power under long-term power purchase arrangements with customers or feed-in tariff arrangements with government entities and utilities. Its SunEdison business is dependent upon government subsidies, including United States federal incentive tax credits, state-sponsored energy credits and foreign feed-in tariffs. The Company�� solar wafers are used as the starting material for crystalline solar cells.
The Company competes with Shin-Etsu Handotai, SUMCO, Siltronic and LG Siltron, SunPower Corporation, First Solar, Inc., Enerparc, Sharp Corporation (Recurrent Energy), Phoenix Solar, BELECTRIC, JUWI Solar Gmbh, and S! olar City! .
Advisors' Opinion:- [By Anna Prior]
SunEdison Inc.(SUNE) on Thursday said it completed its purchase of AES Corp.'s(AES) 50% ownership stake in the Silver Ridge Power LLC joint venture.
- [By Lisa Levin]
SunEdison (NYSE: SUNE) shares surged 0.50% to reach a new 52-week high of $13.99. SunEdison's trailing-twelve-month revenue is $2.06 billion.
Posted-In: 52-Week HighsNews Intraday Update Markets Movers
- [By Jake L'Ecuyer]
SunEdison (NYSE: SUNE) was also on the rise, gaining a staggering 17.06 percent to $12.48 after the company reported a strong third quarter report and the solar sector as a whole continued to show strength.
Top Performing Stocks To Buy For 2014: California Grapes International Inc (CAGR)
California Grapes International, Inc., formerly China Food Services, Corp., incorporated in 1992, conducts its primary business operations as an importer, exporter and distributor of staple, organic, specialty, and gourmet foods and beverages, catering to the Asian Pacific Rim. The Company owns and operates Golden Dragon Food & Beverage Import & Export Company of Hong Kong, Ltd. (GDHK) in central Hong Kong and Beijing Flying Golden Dragon International Trading Co., Ltd. in China (BFGD). Golden Dragon Holdings, Inc. has agreements with the United State food manufacturers. It acts as a buying agent for GDHK, negotiating vendor contracts and services with the United States food and beverage industry partners.
The Company focuses to offer wholesale food distribution to grocery chains and independent food stores throughout China. The Company focuses on purchasing goods directly from manufactures in the United States, Latin America and Europe, and distributes these products to distributors, grocery stores, supermarkets and hypermarkets throughout China.
Advisors' Opinion:- [By abirk]
The smokeable products category (cigarettes and cigars) has grown income at a compounded annual growth rate (CAGR) of 4.2%. In 2013, income from smokeable products was $6.4 billion, up from $5.2 billion in 2008.
- [By Sam Stovall]
1) He could have owned the S&P 500 all year long from April 30, 1990 through October 25, 2013. He would have earned a compound annual growth rate (CAGR) of 8.0%, excluding dividends reinvested.
- [By Julie Young]
In 2013 the Microsoft Business segment generated revenue of $24.7 billion with a three-year compound annual growth rate (CAGR) of 8.7%. Operating income grew steadily ending 2013 at $16.2 billion with a three-year CAGR of 11%. Revenue in the Microsoft Business segment is primarily derived from Office products which generate over 90% of sales for the segment. This segment appears set for continued growth as demand remains high for Office products.
- [By John Emerson]
Open any Berkshire Hathaway (BRK.A)(BRK.B) annual letter and the first thing you see will be a listing of the yearly gains in the book value per share of BRK.A from 1965 to the present year. At the bottom of the year-by-year synopsis lies the compounded annual growth rate (CAGR) of those gains in equity. Later in the article I will show the mathematical formula for calculating those compound gains.
Top Performing Stocks To Buy For 2014: Sprott Physical Gold Trust (PHYS)
Sprott Physical Gold Trust (the Trust) is a closed-end mutual fund trust. The Trust was created to invest and hold substantially all of its assets in physical gold bullion. The Trust seeks to provide an exchange-traded investment alternative for investors interested in holding physical gold bullion. The Trust invests primarily in long-term holdings of unencumbered, fully allocated, physical gold bullion and does not speculate with regard to short-term changes in gold prices. Sprott Asset Management LP (the Manager) is the manager and RBC Dexia Investor Services Trust (RBC Dexia), a trust company, is the trustee of the Trust.
The Trust employs two custodians. The Royal Canadian Mint (Mint) acts as custodian for the Trust's physical gold bullion, pursuant to a precious metals storage agreement between the Manager, for and on behalf of the Trust, and the Mint, to which it refers as the precious metals storage agreement. RBC Dexia acts as custodian of the Trust's assets other than physical gold bullion pursuant to the trust agreement. As of December 31, 2010, the Trust held 90% of its total net assets in physical gold bullion in London Good Delivery bar form. The Trust does not invest in gold certificates or other financial instruments that represent gold or that may be exchanged for gold.
In making investments on behalf of the Trust, the Manager is subject to certain investment and operating restrictions, to which the Trust refers to as the Investment and Operating Restrictions. The Investment and Operating Restrictions provide that the Trust will invest in and hold a minimum of 90% of the total net assets of the Trust in physical gold bullion in London Good Delivery bar form and hold no more than 10% of the total net assets of the Trust, at the discretion of the Manager, in physical gold bullion (in London Good Delivery bar form or otherwise), gold coins, debt obligations of or guaranteed by the Government of Canada or a province of Canada or by the Government of the United St! ates or a state thereof.
The Trust will invest in short-term commercial paper obligations of a corporation or other person whose short-term commercial paper is rated R-1 (or its equivalent, or higher) by Dominion Bond Rating Service Limited or its successors, or assigns or F1 (or its equivalent, or higher) by Fitch Ratings or its successors, or assigns or A-1 (or its equivalent, or higher) by Standard & Poor's or its successors, or assigns or P-1 (or its equivalent, or higher) by Moody's Investor Service or its successors, or assigns, interest-bearing accounts and short-term certificates of deposit issued or guaranteed by a Canadian chartered bank or trust company, money market mutual funds, short-term government debt or short-term investment grade corporate debt, or other short-term debt obligations approved by the Manager from time to time. The Trust will not purchase, sell or hold derivatives.
Advisors' Opinion:- [By Cameron Swinehart]
Going forward I will be looking to add investments on my watchlist and trim other positions. It will be interesting to see how an overweight commodity portfolio will perform relative to the rest of the market.
Cost Basis# SharesCurrent Price% of PortfolioCurrent ValueReturnMetal/Miners Sprott Physical Gold Trust (PHYS)$12.4985$11.043.75%$938.40-13.13%Sprott Physical Silver Trust (PSLV)$7.95125$8.744.37%$1,092.509.04%FreePort-McMoran (FCX)$31.6731$33.874.20%$1,049.976.50%Ishares MSCI Global Gold Miners ETF (RING)$13.0695$10.644.04%$1,010.80-22.74%Energy Statoil ASA(STO)$21.7940$22.683.63%$907.203.92%Vanguard Natural Resources LLC (VNR)$27.5636$27.874.01%$1,003.321.11%ConocoPhillips (COP)$63.6822.43$71.006.37%$1,592.5310.31%Agriculture CVR Partner LP (UAN)$26.3630.9$18.932.34%$584.94-39.25%Adecoagro$6.78125$7.443.72%$930.008.87%Archer-Daniels Midland (ADM)$34.8030$37.244.47%$1,117.206.55%Mixed Commodity Powershares DB Commodity Index (DBC)$26.3540$25.954.15%$1,038.00-1.54%Sprott Resource Corp$3.34400$2.714.34%$1,084.00-23.25% Total % of portfolio49.40% Cost Basis12,666.00 Current Value12,348.86 Return-2.50% Source: Investing For The Future Surge In Commodity PricesDisclosure: I am long ADM, FCX, UAN, AGRO, RING, VNR, SCPZF.PK, COP, DBC, PHYS, PSLV. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)
Top Performing Stocks To Buy For 2014: Synta Pharmaceuticals Corp.(SNTA)
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drug candidates for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its oncology product portfolio includes Ganetespib, an Hsp90 inhibitor in various phase 1, 2, and 3 clinical trail programs for various types of cancers, including non-small cell lung cancer, gastrointestinal stromal tumors, hematologic cancers, colorectal cancer, gastric cancer, small cell lung cancer, ocular melanoma, pancreatic cancer, prostate cancer, breast cancer, hepatocellular cancer, and solid tumors; Elesclomol, a mitochondria-targeting agent in phase 2 clinical trails for non-small cell lung cancer and ovarian cancer, as well as in phase 1 clinical trail for acut e myeloid leukemia; STA-9584, a vascular disrupting agent in preclinical development stage for prostate cancer; and various Hsp90 inhibitors in preclinical development stage for cancers. The company?s inflammatory diseases product portfolio includes calcium release activated calcium modulator (CRACM) channel inhibitors in preclinical development stage for autoimmune diseases, respiratory conditions, and transplantation; and IL-12/23 inhibitors in lead optimization stage for autoimmune diseases. It has a license agreement with Hoffman-La Roche for the development and commercialization of compounds from CRACM. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Synta Pharmaceuticals (NASDAQ: SNTA ) , a clinical-stage biopharmaceutical company focused on researching and developing cancer and chronic inflammatory therapies, fell as much as 17% following an analyst downgrade after Synta disclosed the departure of its president of research & development.
- [By John Udovich]
Small cap NASDAQ stocks Vera Bradley, Inc (NASDAQ: VRA), Ebix Inc (NASDAQ: EBIX) and Synta Pharmaceuticals Corp. (NASDAQ: SNTA) had the highest short interest as of late September according to HighShortInterest.com with short interest of 57.46%, 52.28% and 47.09%, respectively. However, shorting a stock can be a dangerous business as the bears can and do sometimes get mauled by the bulls. With that in mind, let�� take a look at why the bulls or the bears may be right or wrong about these three shorted small cap stocks:�
- [By Sean Williams]
It wasn't all rose petals and sunshine, though, as Synta Pharmaceuticals (NASDAQ: SNTA ) was absolutely decimated after reporting its phase 2b/3 results on its second-line non-small cell lung cancer treatment ganetespib. The results were generally positive, with the combination of ganetespib and docetaxel improving median overall survival to 9.8 months from 7.4 months in the docetaxel-only arm. The worry among investors is that this data may not be significant enough to merit an approval by the FDA. Ganetespib's median overall survival was more pronounced in those who were diagnosed six months or more before the study, which could lead to a selective approval there, but it would definitely limit its market potential.�
No comments:
Post a Comment